New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - prochlorperazine maleate 5mg - tablet - 5 mg - active: prochlorperazine maleate 5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch - for treatment of nausea associated with migraine.

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine maleate tablets are effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of  prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine maleate tablets as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that p

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - prochlorperazine maleate -

Malta - English - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - prochlorperazine maleate - tablet - prochlorperazine maleate 5 mg - psycholeptics

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - prochlorperazine maleate 5mg - tablet - 5 mg - active: prochlorperazine maleate 5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch - prochlorperazine maleate is used in vertigo due to meniere's syndrome, labyrinthitis and other causes, and for nausea and vomiting from whatever cause. it may also be used for migraine, schizophrenia (particularly in the chronic stage), acute mania and as an adjunct to the short term management of anxiety.

United States - English - NLM (National Library of Medicine)

sandoz inc - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - prochlorperazine maleate 5mg - suppository - 5 mg - active: prochlorperazine maleate 5mg excipient: suppository base e75 suppository base w35

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazinewill be useful in patients with other non-psychotic conditions in wh

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with othe

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with othe